KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.96

Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Charlene M Mantia, Opeyemi A Jegede, David F McDermott, Daniel Y C Heng, Wanling Xie, Toni K Choueiri, Michael B Atkins, Meredith M Regan

JCO Oncol Pract 22(5) 804-812

PMID40658913
PMCIDPMC12262164
DOI10.1200/OP-25-00089
发表日期2025-07-14
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: In the era of prolonged survival for advanced renal cell carcinoma (aRCC) with standard-of-care first-line therapy now including immune checkpoint inhibitor, re-evaluation of the Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic RCC Database Consortium (IMDC) prognostic models is overdue. METHODS: Data from 1,052 patients with aRCC treated on the CheckMate-214 phase III randomized trial with first-line nivolumab + ipilimumab or sunitinib were analyzed after minimum 5 years of follow-up. The end point was overall survival (OS). To investigate long-term prognostication with each treatment approach, model performance based upon continuous risk score was assessed in a time-dependent manner of increasing 6-month intervals and globally over full follow-up, using discrimination concordance (c)-indices. RESULTS: With time-dependent assessment, the IMDC and MSKCC models maintained their performance over approximately 2 years from sunitinib initiation (c ≥0.69 through 18-24 months); thereafter, the models' performances with long-term OS attenuated. Over full follow-up, the models' discrimination was c = 0.66 (95% CI, 0.658 to 0.664) and c = 0.64 (95% CI, 0.640 to 0.645), respectively, for the sunitinib group. After nivolumab + ipilimumab initiation, the IMDC and MSKCC models' global discrimination was c = 0.63 (95% CI, 0.628 to 0.634) and c = 0.61 (95% CI, 0.607 to 0.614), respectively. The models' performances were attenuated in the short term (c ranging 0.64-0.69 through 18-24 months) and the long term. CONCLUSION: This retrospective analysis of the CheckMate-214 trial, in which nivolumab + ipilimumab improved survival versus sunitinib with 48% and 37% of patients, respectively, surviving beyond 5 years, confirmed the strength of the models' prognostication for the early years after first-line sunitinib initiation continuing to stratify three prognostic categories, but also diminished discrimination among long-term survivors and with initiation of nivolumab + ipilimumab. As novel treatments are developed and patients with aRCC live longer, new models to estimate long-term prognosis are needed.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1.

Overall survival (OS) distribution (A,B) and smoothed OS hazard function (C,D) estimates according to the three IMDC prognostic risk categories, in the CheckMate-214 trial treatment groups. Abbreviations: IMDC=International Metastatic Renal Cell Carcinoma Database Consortium

OS_Distribution_of_IMDC_Risk_Categories

overall survival

Figure 1. · Panel OS_Distribution_of_IMDC_Risk_Categories

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel OS_Distribution_of_IMDC_Risk_Categories 是同一 Figure 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2.Time-dependent prognostic value of the IMDC model in the CheckMate-214 trial treatment groups, as discerned from scaled Schoenfeld residuals from the Cox regression of overall survival on the continuous IMDC prognostic scores (upper panels) or on the count of IMDC prognostic factors (lower panels). The solid black curve is a spline fit for visualization, dashed black curves are confidence bands of ± 2 standard errors. The curve would be horizontal at a non-zero value in the absence of time-dependent relationship, but revealed attenuation of prognostic value with longer overall survival since first-line treatment initiation. Abbreviations: IMDC=International Metastatic Renal Cell Carcinoma Database Consortium
非 KM Figure
Figure 3.Time-dependent and global discrimination of the MSKCC and IMDC models in the CheckMate 214 trial treatment groups, as discerned from concordance (c)-indices from the Cox regression of overall survival on the continuous prognostic scores. Uno’s method [ 17 ] estimated c-indices over increasing follow-up time intervals to 60 months since randomization; Harrell’s method [ 16 ] estimated a global c-index over the entirety of follow-up. Abbreviations: MSKCC= Memorial Sloan Kettering Cancer Center; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium
非 KM Figure